Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.